Can αIIbβ3 Receptor Play a Role in Platelet Production – Glanzmann’s Research Foundation
Glanzmann’s Research Foundation shared a post on LinkedIn about a recent article by Kato Ramaekers et al., published in Blood, adding:
New research is giving us a closer look at what may be happening with platelets in Glanzmann Thrombasthenia.
The study suggests that αIIbβ3, the platelet receptor affected in GT, may play a role not only in platelet function but also in platelet production.
Researchers also identified a potential connection between αIIbβ3, serine metabolism, and platelet formation.
This is early research, not proof that people with GT produce fewer platelets.
More research is needed to understand what these findings mean for people living with GT.
Read our plain-language breakdown of the study and what it could mean for the future of GT research.”
Title: Reduced platelet formation associated with serine metabolic dysregulation in integrin α β –deficient megakaryocytes
Authors: Kato Ramaekers, My Tran, Marco Lunghi, Amy Hermans, Chantal Thys, Koenraad De Wispelaere, Ernest Turro, Chris Van Geet, Quentin Van Thillo, Kathelijne Peerlinck, Koji Eto, Alan T. Nurden, Alessandra Balduini, Christian A. Di Buduo, Veerle Labarque, Kathleen Freson
More posts featuring Glanzmann’s Research Foundation on Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian